A phase 2 trial of Lundbeck’s alpha-synuclein-targeting drug Lu AF82422 has failed to reach statistical significance in patients with multiple system atrophy (MSA), althou
Shares in BioXcel Therapeutics rose more than 31% in early trading today after the biotech said an independent audit of a phase 3 trial of its Alzheimer’s disease therapy
Lundbeck and Otsuka’s Rexulti has become the first drug to be approved by the FDA to treat agitation associated with Alzheimer’s disease, a common symptom of the neurodege
Otsuka and Lundbeck’s antidepressant Rexulti should be approved to treat Alzheimer’s disease-related agitation (AAD), according to FDA advisors – a move that could unlock
Selective serotonin reuptake inhibitors (SSRIs) are the first-line drug therapy of choice for most people suffering from depression but often fail to work effectively.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.